BTIG Rates Edwards Lifesciences (EW) buy, $110 Price Target

BTIG reaffirms its bullish stance on Edwards Lifesciences, matching the highest price target among covering Wall Street firms, a 21.60% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 8:01 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG rated Edwards Lifesciences Corporation ($EW) "buy" with a $110 price target on June 30, 2026.

Since the rating, $EW is up 4.8% after 1 week, down 3.9% after 1 month and down 4.3% to date (from the $90.46 close on Jun 30, 2026).

EW Edwards Lifesciences Corporation

$86.60 +1.49% year to date

Daily close · Oct 16, 2026

Key Points

BTIG analyst Marie Thibault reiterated a buy rating on Edwards Lifesciences Corporation (NYSE: EW) with a price target of $110.00 on June 30, 2026.
BTIG's $110 price target implies 21.60% upside from Edwards Lifesciences Corporation's ($EW) current $90.46 share price.
The medical device maker trades near $90.46, sitting above its 200-day moving average of $85.02 and well below its 52-week high of $96.29.
Wall Street maintains a consensus buy recommendation on the stock with a mean price target of $100.96 across 26 analyst opinions.

Get $EW trade alerts by text

We text you when insiders, Congress or big funds trade $EW. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Edwards Lifesciences Corporation alert may contain errors. Disclosures

BTIG Reaffirms Bullish Call on Edwards Lifesciences

BTIG analyst Marie Thibault maintained a buy rating on Edwards Lifesciences Corporation (NYSE: EW) on June 30, 2026, keeping a price target of $110.00. That target matches the highest goal set across the analyst community for the medical device provider. The firm's renewed stance places it on the more optimistic side of the street, aligning with a handful of peers who see substantial upside from current trading levels.

Analyst rating track record

BTIG vs. the S&P 500

YTD return -22.38% hypothetical

All-time return +27.09% S&P 500 +39.96%

vs. S&P 500 -12.87% behind the index

Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.

How BTIG Compares to Wider Analyst Views

Wall Street firms have regularly updated their outlooks for the company over recent months. On October 7, 2026, Barclays initiated coverage with an Overweight rating and a $110.00 price target. Earlier in the summer, on July 25, 2026, Leerink Partners upgraded the stock to an Outperform and lifted its target to $101.00 from $87.00. JP Morgan maintained an Overweight rating on July 24, 2026, raising its target to $105.00 from $100.00. Piper Sandler also kept an Overweight rating on July 24, 2026, adjusting its target to $101.00 from $100.00. Truist Securities maintained a hold rating on July 16, 2026, while moving its target to $95.00 from $90.00. Mizuho maintained an Outperform rating on July 15, 2026, setting a $105.00 target. RBC Capital also kept an Outperform rating on July 13, 2026, raising its target to $110.00 from $100.00. Overall, the stock holds a consensus buy recommendation with a mean price target of $100.96 drawn from 26 analyst opinions, with targets ranging from a low of $84.00 up to that $110.00 peak.

Edwards Lifesciences Stock Valuation and Trading Range

Shares of Edwards Lifesciences recently traded around $90.46. That price sits comfortably above the 200-day moving average of $85.02 and close to the 50-day moving average of $88.51. Over the past year, the stock has moved between a 52-week low of $72.30 and a 52-week high of $96.29. The company carries a forward P/E ratio of 26.16 based on earnings estimates, alongside a total market capitalization of roughly $50.92 billion.

12-month forecast

$EW price target

Edwards Lifesciences Corporation daily closes and this analyst's $110 target. Not advice.

What Edwards Lifesciences Does

Based in Irvine, California, Edwards Lifesciences focuses on medical technologies that treat advanced cardiovascular diseases. The company designs transcatheter heart valve replacement systems like the SAPIEN family, alongside repair tools for mitral and tricuspid valve conditions under the PASCAL and EVOQUE brands. It also builds surgical structural heart solutions, including the INSPIRIS RESILIA aortic valve and MITRIS RESILIA products, distributing its equipment globally through a direct sales force and independent partners.

What to Watch Next for the Stock

Investors will look toward the next earnings release scheduled for October 29, 2026, to gauge how well the company's valve technologies are selling worldwide. Market participants will also track whether other major investment banks adjust their price targets to match BTIG and RBC Capital at the $110.00 level as the year winds down.